Posted by Michael Wonder on 19 Jan 2018
Avion Pharmaceuticals announces approval of first NDA in the oral contraceptive category
18 January 2018 - Avion Pharmaceuticals received approval of its new drug application for the oral contraceptive Balcoltra (levonorgestrel and ethinyl estradiol tablets and ferrous bisglycinate tablets), the company's first internally developed new drug application.
Avion expects to commercially launch this new oral contraceptive to the prescribing community in Spring 2018.
The approval of Balcoltra, the only branded oral contraceptive combining 0.1 mg levonorgestrel, 20 mcg ethinyl estradiol tablets and ferrous bisglycinate tablets 36.5 mg, marks a milestone for Avion Pharmaceuticals and a win for the women's health category by allowing women to have access to a clinically effective form of oral contraception for pregnancy prevention.
